Compare Tidewater Inc (TDW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Tidewater Inc trades at $85.42 (market cap $4.21B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.4× Tidewater Inc's market cap, and Tidewater Inc is more actively traded (590,005 versus 12,903,266). Which is the better fit depends on your goals — on Pluang, investors hold Tidewater Inc for 26 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TDW | XBI | |
|---|---|---|
Market Cap | $4.21B | $10.11B |
Volume | 590,005 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $100.61 | $169.55 |
52-Week Low | $47.29 | $104.99 |
Typical Hold Time | 26 Days | 38 Days |
Enterprise Value | $4.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $84.70, up 1.56% today, with a bullish technical signal from moving averages and a consensus analyst price target of $105.50. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 shows a decline. Recent news includes the completion of the Wilson Sons Ultratug acquisition and significant institutional buying by BlackRock.
The stock offers upside to the price target but faces risks from earnings volatility, as seen in recent quarterly misses, and exposure to energy market cycles. Investor sentiment is mixed with a majority hold rating from analysts, indicating cautious optimism amid operational execution challenges.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
